Antares Pharma, Inc.

ATRSCIK 0001016169 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 29, 2022. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone 0.0014

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Antares Pharma, Inc.

Name	Roles	Filings
Greenleaf Peter	Director	1
Jacob Leonard S	Director	1
Roche Robert P Jr	Director	1
Richardson Peter C	Officer	1
Smith Karen L.	Director	1

Showing 6-10 of 11

Per pagePrevPage 2 of 3Next

All filings

17 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
May 26, 2022	Graham Peter J See Remarks	DDisposition	414,470	$5.60	$2,321,032
May 26, 2022	Jacob Leonard S Director	DDisposition	138,901	$5.60	$777,846
May 26, 2022	Smith Karen L. Director	DDisposition	54,193	$5.60	$303,481
May 26, 2022	Richardson Peter C See Remarks	DDisposition	36,199	$5.60	$202,714
May 26, 2022	Gueth Anton Director	DDisposition	386,132	$5.60	$2,162,339

Showing 6-10 of 17

Per pagePrevPage 2 of 4Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value